Displaying drugs 11151 - 11175 of 11481 in total
MB-102 CD123 CAR
MB-102 are autologous T cells genetically modified to express CD123-specific, hinge-optimized CD28-costimulatory chimeric receptor and a truncated human epidermal growth factor receptor.
Investigational
Matched Description: … genetically modified to express CD123-specific, hinge-optimized CD28-costimulatory chimeric receptor and a …
Erfonrilimab
Erfonrilimab is a bispecific monoclonal antibody directed against both the programmed cell death-1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4).
Investigational
Matched Description: … Erfonrilimab is a bispecific monoclonal antibody directed against both the programmed cell death-1 ligand …
Tandutinib
MLN518 is a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases, including FLT3, (platelet-derived growth-factor receptor) PDGFR and c-KIT. Tyrosine kinases are enzymes involved in several cellular processes and are known to be activated in cancer cells to drive tumor growth. AML patients with FLT3 mutations...
Investigational
Matched Description: … Approximately 25 to 30 percent of all adult AML patients have a mutation of the FLT3 gene. ... MLN518 is a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases, including …
Cefovecin
Cefovecin is a cephalosporin antibiotic used for the treatment of skin infections in cats and dogs. It is the first single-dose injectable antibiotic for dogs and cats that assures owner compliance with dosing for the animal. It is used for the treatment of skin infections caused by Pasturella multocida in...
Experimental
Vet approved
Matched Description: … Cefovecin is a cephalosporin antibiotic used for the treatment of skin infections in cats and dogs. ... The advantage of using injectable antibiotics is not missing a dose that can allow partially resistant …
IMM101
IMM-101 is a heat-inactivated immune-activating mycobacterial product. It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma [PMID: 21930686; PMID: 30107850; PMID: 27599039]. Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help...
Investigational
Matched Description: … IMM-101 is a heat-inactivated immune-activating mycobacterial product. ... partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a …
Marimastat
Used in the treatment of cancer, Marmiastat is an angiogenesis and metastasis inhibitor. As an angiogenesis inhibitor it limits the growth and production of blood vessels. As an antimetatstatic agent it prevents malignant cells from breaching the basement membranes.
Investigational
CAD106
CAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease. It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients.
Investigational
3,5-Diiodotyrosine
A product from the iodination of MONOIODOTYROSINE. In the biosynthesis of thyroid hormones, diiodotyrosine residues are coupled with other monoiodotyrosine or diiodotyrosine residues to form T4 or T3 thyroid hormones (THYROXINE and TRIIODOTHYRONINE). [PubChem]
Experimental
Matched Description: … A product from the iodination of MONOIODOTYROSINE. …
N-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-L-prolinamide
N-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-l-prolinamide is a solid. This compound belongs to the alpha amino acid amides. These are amide derivatives of alpha amino acids. This medication targets the protein prothrombin.
Experimental
Matched Description: … N-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-l-prolinamide is a solid. …
Ultevursen
Ultevursen is a single-stranded RNA-based oligonucleotide targeting exon 13 of the USH2A gene that encodes usherin. It was developed by ProQR Therapeutics and is being investigated for the treatment of retinitis pigmentosa.
Investigational
Matched Description: … Ultevursen is a single-stranded RNA-based oligonucleotide targeting exon 13 of the USH2A gene that encodes …
ETC-588
ETC-588, or LUV (large unilamellar vesicles), is made of naturally occurring lipids that circulate through arteries to facilitate the role of high-density lipoprotein (HDL) in removing accumulated cholesterol and other lipids from cells including those in the arterial wall. LUV are capable of transporting excess cholesterol from the vasculature to...
Investigational
Matched Description: … Esperion is currently developing ETC-588 as a treatment for patients with acute coronary syndromes. …
Cositecan
Cositecan is the novel camptothecin derivative which is also known as Karenitecin. It has been developed for superior oral bioavailability and increased lactone stability. It is used to treat cancer.
Investigational
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine
25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist. It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion . It was discovered in 2014 at the University of Copenhagen.
Experimental
Matched Description: … 25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective …
Pranlukast
Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.
Investigational
Matched Description: … Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. …
CPD 923
CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile.
Investigational
Matched Description: … It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile. …
Talopram
Talopram is a selective norepinephrine reuptake inhibitor (SNRI) that is structurally similar to citalopram and melitracen. It was researched in the 1960s and 1970s but never marketed.
Experimental
Matched Description: … Talopram is a selective norepinephrine reuptake inhibitor (SNRI) that is structurally similar to citalopram …
GDC-0927
GDC-0927 is under investigation in clinical trial NCT02316509 (A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer).
Investigational
Matched Description: … GDC-0927 is under investigation in clinical trial NCT02316509 (A Study of GDC-0927 in Postmenopausal …
BMS-986141
BMS-986141 is under investigation in clinical trial NCT02985632 (A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants).
Investigational
Matched Description: … BMS-986141 is under investigation in clinical trial NCT02985632 (A Study to Evaluate the Pharmacokinetics …
Licogliflozin
Licogliflozin is under investigation in clinical trial NCT03320941 (A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity).
Investigational
Matched Description: … Licogliflozin is under investigation in clinical trial NCT03320941 (A Dose-finding Study to Evaluate …
CR6086
CR6086 is under investigation in clinical trial NCT03163966 (A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in Dmard-naïve Patients With Early Rheumatoid Arthritis).
Investigational
Matched Description: … CR6086 is under investigation in clinical trial NCT03163966 (A Study of the EP4 Antagonist CR6086 in …
Paltusotine
Paltusotine is under investigation in clinical trial NCT04261712 (A Study to Evaluate the Long-term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)).
Investigational
Matched Description: … Paltusotine is under investigation in clinical trial NCT04261712 (A Study to Evaluate the Long-term Safety …
Oxelumab
Oxelumab is under investigation in clinical trial NCT00983658 (A Study of HuMAb OX40L in the Prevention of Allergen-induced Airway Obstruction in Adults With Mild Allergic Asthma).
Investigational
Matched Description: … Oxelumab is under investigation in clinical trial NCT00983658 (A Study of HuMAb OX40L in the Prevention …
Elacytarabine
Elacytarabine is a fatty acid derivative of cytarabine, an approved cytotoxic cancer drug. Cytarabine has limitations such as minimal uptake in solid tumours and is only used to treat leukaemia. Elacytarabine is designed to overcome this limitation and has shown considerable uptake in solid tumour cells. Elacytarabine is a patented...
Investigational
Matched Description: … Elacytarabine is a fatty acid derivative of [cytarabine], an approved cytotoxic cancer drug. ... Elacytarabine is a patented new chemical entity of the nucleoside analog class, with improved biological …
KBP-COVID-19
The KBP-201 COVID-19 Vaccine was developed by British American Tobacco’s (BAT) U.S. biotech subsidiary, Kentucky BioProcessing (KBP). KBP cloned COVID-19’s genetic sequence, identified a potential antigen, and then inserted it into tobacco plants for reproduction. Upon harvest, the antigens were purified, and these components underwent preclinical testing in animals. As...
Investigational
Matched Description: … KBP cloned COVID-19’s genetic sequence, identified a potential antigen, and then inserted it into tobacco ... As of July 2020, KBP is conducting a Phase 1/2 clinical trial to evaluate the safety and immunogenicity …
HGS-TR2J
HGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies. It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.
Investigational
Matched Description: … HGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced …
Displaying drugs 11151 - 11175 of 11481 in total